MTNB News & Events

Matinas BioPharma announced that it received a notice from the NYSE stating that the company is not in compliance with the NYSE American continued listing standards set forth in Section 1003 of the NYSE American Company Guide requiring a company to have stockholders' equity of at least $4M if it has reported losses from continuing operations and/or net losses in three of its four most recent fiscal years. As of March 31, the company had stockholders' equity of $3.02M and has had losses in the most recent five fiscal years ended December 31, 2025.

Matinas BioPharma files $150M mixed securities shelf

Cadrenal Therapeutics (CVKD) announced a leadership transition appointing James Ferguson as its new chief medical officer, effective immediately. Ferguson will lead the late-stage clinical development of tecarfarin to include the pivotal trial in LVAD patients and other indications in rare cardiovascular conditions requiring life-long anticoagulation therapy as well as other business development opportunities to build the company's pipeline. Ferguson replaces Douglas Losordo. Ferguson joins Cadrenal after serving as chief medical officer at Matinas BioPharma (MTNB).